All congress activities

Watch our hybrid Industry Forum at MDA 2022, which discusses the latest clinical findings on the role of corticosteroid treatment in the management of Duchenne muscular dystrophy (DMD) 

View the key takeaways from our MDA 2022 Virtual Industry Forum, which summarizes the role of corticosteroids in the treatment of patients with Duchenne muscular dystrophy (DMD)

Presented at the 2022 AAN Annual Meeting in Seattle, USA, this poster shows results from a study investigating disease progression following treatment with different corticosteroids for Duchenne muscular dystrophy (DMD)

This poster, presented at the 2022 AAN Annual Meeting in Seattle, USA, presents the results of a comparison of corticosteroid treatments in non-ambulatory patients with DMD

This poster, presented at the 2022 14^th EPNS Congress in Glasgow, discusses the functional outcomes of patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) receiving a mutation-specific DMD therapy in real-world practice versus a clinical trial setting

View an analysis of motor function in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) receiving ataluren in real-world practice versus a clinical trial setting in our poster presented at EPNS 2022

This poster, presented at the 2022 MDA Conference in Nashville, Tennessee, USA, shows the results of a study comparing 2 corticosteroids in delaying disease progression milestones in patients with DMD

This poster from the 2022 MDA Conference in Nashville, Tennessee, USA, presents results from a study comparing clinical outcomes in patients with Duchenne muscular dystrophy (DMD) by corticosteroid type within distinct patient subgroups

This poster, presented at the 2022 MDA Conference in Nashville, Tennessee, USA, reports the results of a comparison of corticosteroid treatments on clinical outcomes in non-ambulatory DMD patients

This poster, from the 2022 MDA Conference in Nashville, Tennessee, USA, presents the ambulatory outcomes observed following treatment for nonsense mutation Duchenne muscular dystrophy (nmDMD) in the STRIDE Registry and Study 020, a Phase 3 clinical trial

This poster, from the 2022 MDA Conference in Nashville, Tennessee, USA, compares the age at loss of ambulation in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) enrolled in the STRIDE Registry and CINRG Natural History Study

This poster, presented at the 2022 MDA Conference in Nashville, Tennessee, USA, shows results from a propensity score-matched registry analysis, using data from the STRIDE Registry and CINRG Natural History Study, to determine the effect of a mutation-specific treatment for nonsense mutation Duchenne muscular dystrophy (nmDMD) on pulmonary function

This poster, presented at the 2022 MDA Conference in Nashville, Tennessee, USA, provides safety data from a registry analysis of boys with nonsense-mutation Duchenne muscular dystrophy (nmDMD)